NASDAQ:MTCR Metacrine (MTCR) Stock Price, News & Analysis → Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown” (From Paradigm Press) (Ad) Free MTCR Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.58▼$0.5950-Day Range$0.55▼$0.5952-Week Range$0.30▼$0.59Volume83,889 shsAverage Volume225,834 shsMarket Capitalization$24.75 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Metacrine alerts: Email Address Ad Paradigm PressMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… About Metacrine Stock (NASDAQ:MTCR)Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.Read More Ad Paradigm PressMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… MTCR Stock News HeadlinesApril 17, 2024 | reuters.comUS says China is boosting Russia's war machine in UkraineDecember 20, 2023 | bbc.comTwitter says hackers downloaded private account dataNovember 9, 2023 | morningstar.comAN2 Therapeutics Inc ANTXJuly 8, 2023 | morningstar.comBeijing Huafeng Test & Control Technology Co Ltd Class AJuly 3, 2023 | nbcnews.com3 children among 9 dead as Russian missile slams into pizza restaurantMarch 31, 2023 | abcnews.go.comGun ControlMarch 21, 2023 | usnews.comGun Control And Gun RightsMarch 20, 2023 | nbcnews.comMajor Russian missile barrage slams targets across UkraineMarch 15, 2023 | bbc.co.ukDnipro missile: Son in search of his motherMarch 9, 2023 | thestreet.comHow Elon Musk Controls Tesla With Only a Minority Ownership StakeFebruary 24, 2023 | forbes.comOld Tax Regime Vs. New Tax Regime: Which Is Better In 2023?December 23, 2022 | finance.yahoo.comMetacrine and Equillium Mutually Agree to Terminate Definitive Merger AgreementNovember 17, 2022 | finanznachrichten.deMetacrine, Inc.: Metacrine Reports Third-Quarter 2022 ResultsNovember 15, 2022 | finance.yahoo.comMetacrine Reports Third-Quarter 2022 ResultsOctober 11, 2022 | marketscreener.comMETACRINE, INC. : Other Events (form 8-K) - Marketscreener.comSeptember 28, 2022 | finance.yahoo.comEquillium Announces Positive Interim Results from the EQUALISE Study in Subjects with Lupus Nephritis - Yahoo FinanceSeptember 25, 2022 | benzinga.comLifshitz Law PLLC Announces Investigations of TALO, SBET, EQ, and MTCR - Metacrine (NASDAQ:MTCR), Equilli - BenzingaSeptember 22, 2022 | benzinga.comLifshitz Law PLLC Announces Investigations of RMED, SBET, EQ, and MTCR - Metacrine (NASDAQ:MTCR), Equilli - BenzingaSeptember 21, 2022 | marketwatch.comLifshitz Law PLLC Announces Investigations of RMED, SBET, EQ, and MTCR - MarketWatchSeptember 19, 2022 | prnewswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ECOM, SGFY, EQ, MTCR - PR NewswireSeptember 17, 2022 | benzinga.comLifshitz Law PLLC Announces Investigations of RMED, SBET, EQ, and MTCR - Metacrine (NASDAQ:MTCR), Equillium (NASDAQ:EQ) - BenzingaSeptember 8, 2022 | benzinga.comMETACRINE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Metacrine Inc. - MTCRSeptember 7, 2022 | globenewswire.comSHAREHOLDER NOTICE: Halper Sadeh LLP Investigates STR, MNRL, EQ, MTCR - GlobeNewswireSeptember 7, 2022 | benzinga.comApexigen, Inc. - Common Stock (APGN), (AQST), (ATIP), (ATXI), Cardiff Oncology, Inc. - Common Stock (CRDF - BenzingaSeptember 7, 2022 | finance.yahoo.comEquillium to Acquire Metacrine in All-Stock Transaction - Yahoo FinanceSee More Headlines Receive MTCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Metacrine and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2021Today6/16/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MTCR CUSIPN/A CIK1634379 Webwww.metacrine.com Phone858-369-7800FaxN/AEmployees10Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-62,210,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-84.88% Return on Assets-59.33% Debt Debt-to-Equity Ratio0.34 Current Ratio12.15 Quick Ratio12.15 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.36 per share Price / Book0.43Miscellaneous Outstanding Shares42,570,000Free Float36,695,000Market Cap$24.75 million OptionableNot Optionable Beta-0.73 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. David M. Maggio (Age 64)Chief Bus. Officer, Pres, CEO, Sec., Treasurer, Principal Financial & Acct. Officer Key CompetitorsLifeVantageNASDAQ:LFVNClearside BiomedicalNASDAQ:CLSDEton PharmaceuticalsNASDAQ:ETONBeyondSpringNASDAQ:BYSIInflaRxNASDAQ:IFRXView All Competitors MTCR Stock Analysis - Frequently Asked Questions How were Metacrine's earnings last quarter? Metacrine, Inc. (NASDAQ:MTCR) announced its earnings results on Thursday, May, 13th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by $0.06. What other stocks do shareholders of Metacrine own? Based on aggregate information from My MarketBeat watchlists, some companies that other Metacrine investors own include Bridgewater Bancshares (BWB), Bank of Commerce (BOCH), Blink Charging (BLNK), Bloomin' Brands (BLMN), Bausch Health Companies (BHC), Bridge Bancorp (BDGE), Bank of America (BAC), AXIS Capital (AXS), Avadel Pharmaceuticals (AVDL) and Blue Apron (APRN). When did Metacrine IPO? Metacrine (MTCR) raised $84 million in an initial public offering on Wednesday, September 16th 2020. The company issued 6,500,000 shares at $12.00-$14.00 per share. Jefferies, Evercore ISI and RBC Capital Markets acted as the underwriters for the IPO and Canaccord Genuity was co-manager. This page (NASDAQ:MTCR) was last updated on 6/16/2024 by MarketBeat.com Staff From Our PartnersGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine...InvestorPlace | SponsoredDouble-Threat Biotech Could Deliver Triple-Digit GainsMost investors haven't heard of this under-the-radar biotech... But it could emerge as one of the premier A...Behind the Markets | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Metacrine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Metacrine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.